stockportfolio.pro
Stocks / HIMS vs IMVT
HIMS vs IMVT
Hims & Hers Health, Inc. and Immunovant, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Hims & Hers Health, Inc. (HIMS) | Immunovant, Inc. (IMVT) | |
|---|---|---|
| Market cap | $6.5B | $6.6B |
| Revenue (latest FY) | $2.35B | $0 |
| Net income (latest FY) | $128.37M | $-505.61M |
| Revenue growth (5y CAGR) | 73.6% | — |
| Net margin | 5.5% | — |
| Return on equity | 23.7% | -59.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HIMS — free Open IMVT — freeFrequently asked questions
Which is bigger, HIMS or IMVT?
Immunovant, Inc. is larger by market capitalization — $6.6B versus $6.5B.
Which grows faster, HIMS or IMVT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.